Drugging RNA with Pills : Small Molecules for a Big Frontier

Sep 6, 20221 min read

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Jul 6, 20222 min read

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

Jul 5, 20223 min read

Skyhawk Therapeutics Completes New Investment Round

Sep 14, 20211 min read

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Sep 13, 20213 min read

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President

Apr 12, 20212 min read

$40M up front: Skyhawk takes flight with Vertex deal

Dec 22, 20203 min read

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

Dec 22, 20202 min read

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

Dec 22, 20202 min read

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

Sep 29, 20202 min read

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

May 11, 20202 min read

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

May 11, 20202 min read

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

May 11, 20202 min read

The 20 under 40 : Inside the next generation of biopharma leaders

Apr 5, 20205 min read

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

Feb 24, 20202 min read

The 20 Startups to Watch in Boston in 2020

Dec 16, 20191 min read

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Nov 12, 20192 min read

Skyhawk’s $80M Celgene deal expands remit to autoimmune

Nov 12, 20191 min read

C&EN’s 2019 10 Start-Ups to Watch

Nov 11, 20194 min read

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene

Nov 9, 20192 min read